Место хромогранина А в современной диагностике нейроэндокринных опухолей


Дзеранова Л.К., Парамонов В.М., Пигарова Е.А.

Обсуждаются вопросы диагностики нейроэндокринных опухолей (НЭО), имеющие принципиальное значение с точки зрения их раннего выявления и лечения. Отмечается, что на сегодня оптимальным биомаркером НЭО является хромогранин А (ХГА). Представлены данные об уровнях ХГА при НЕЭ различной локализации и использовании его определения для оценки эффективности лечения НЭО и их прогноза. Подчеркивается, что из терапевтических методов лечения наиболее перспективным является назначение синтетических аналогов соматостатина, причем наиболее доказанным является терапевтическое действие препарата Сандостатин ЛАР.

Литература


1. Konecki DS, Benedum UM, Gerdes HH, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem 1987;262:17026–30.
2. Granberg D, Stridsberg M, Seensalu R et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999;84:2712–17.
3. Fossmark R, Jianu CS, Martinsen TC, et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008;43:20–4.
4. Tomasseti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumors. Eur J Gastroenterol Hepatol 2001;13:55–8.
5. Stivanello M, Berruti A, Torta M, et al. Circulating chromogranin A in the assesment of patients with neuroendocrine tumors. A single institution experience. Ann Oncol 2001;12(Suppl 2):S73–77.
6. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a usefuk marker of neuroendocrine tumors? J Clin Oncol 2007;25:967–73.
7. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic sntigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999; 86:858–65.
8. Kalkner KM, Janson ET, Nilsson S, et al. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res 1995;55(23 Suppl):5801s–4s.
9. Panzuto F, Severi C, Cannizzaro R, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 2004;27:6–11.
10. Stridsberg M, Oberg K, Li Q, et al. Measurment of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumors and endocrine pancreatic tumors. J Endocrinol 1995;144: 49–59.
11. Nobels FR, de Herder WW, Kwekkeboom DJ, et al. Serum chromogranin A in the differential diagnosis of Cushings syndrome. Eur J Endocrinol. 1994; 131: 589–93.
12. Cimitan M, Buonadonna A, Cannizzaro R, et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol. 2003;14:1135–41.
13. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an “on/off” switch controlling dense core secretory granule biogenesis. Cell. 2001;106:499–509.
14. Nikou GC, Marinou K, Thomakos P, et al. Chromogranin A levels in diagnosis, treatment and follow-up of 42 patients with nonfunctioning pancreatic endocrine tumors. Pancreatology. 2008;8:510–19.
15. Janson ET, Holmberg L, Stridsberg M et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997; 8:685–90.
16. Korse CM, Bonfrer JM, Aaronson NK, Haart AA et al. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology 2009;89:296–301.
17. Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of phase II study. J Clin Oncol 2008;26:4311–18.
18. Korse CM, Taal BG, de Groot CA et al. Chromogranin A and N-terminal probrain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009;27:4293–99.
19. Welin S, Stridsberg M et al. Elevated plasma chromogranin A is the first indication of reccurence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009; 89:302–07.
20. Kidd M, Moldlin IM, Mane SM et al. QRT-PCR detection of chromogranin A: a new standart in the identification of neuroendocrine tumor disease. Ann Surg 2006;243:273–80.


Похожие статьи


Бионика Медиа